Quantitative myocardial blush score (QuBE) allows the prediction of heart failure development in long-term follow-up in patients with ST-segment elevation myocardial infarction: Proof of concept study.


Journal

Cardiology journal
ISSN: 1898-018X
Titre abrégé: Cardiol J
Pays: Poland
ID NLM: 101392712

Informations de publication

Date de publication:
2019
Historique:
received: 08 01 2017
accepted: 17 09 2017
revised: 17 09 2017
pubmed: 14 11 2017
medline: 7 7 2020
entrez: 14 11 2017
Statut: ppublish

Résumé

Acute myocardial infarction (AMI) might lead to left ventricular remodeling. Adequate myocardial perfusion is critical to prevent this adverse remodeling. Quantitative myocardial blush evaluator (QuBE) software, available on-line, is a simple analysis tool which enables the precise quan-tification of myocardial perfusion in the infarct area immediately after interventional treatment. The aim of this study was to assess whether the results of QuBE analysis might predict the development of heart failure (HF) in AMI patients in 3 year-long follow-up. Ninety five patients with first AMI, single vessel coronary artery disease, Killip class I at presentation were enrolled in the study. Angiograms were reanalyzed using the on-line QuBE software. Data on heart failure development (ICD 10 codes I50) provided by the National Health Fund were considered as primary outcome. QuBE values ranged from 0.0 to 25.3 arbitrary units, mean value was 9.9 ± 5.2 arbitrary units. QuBE correlated positively with myocardial blush grade (MBG; Spearman R = 0.342 at p < 0.05). Multivariate Cox proportional hazard modeling, adjusted for initial Thrombolysis in Myocardial In-farction (TIMI flow, and TIMI thrombus grade indicated QuBE score (1 unit increase - HR 0.919, 95% CI 0.846-0.999, p = 0.049) and left ventricular ejection fraction at discharge (1% increase - HR 0.936, 95% CI 0.902-0.971, p = 0.000) as independent predictors of HF development. The QuBE assessment of myocardial perfusion allows the prediction of HF development in the post-infarction period in this highly selective group of patients.

Sections du résumé

BACKGROUND
Acute myocardial infarction (AMI) might lead to left ventricular remodeling. Adequate myocardial perfusion is critical to prevent this adverse remodeling. Quantitative myocardial blush evaluator (QuBE) software, available on-line, is a simple analysis tool which enables the precise quan-tification of myocardial perfusion in the infarct area immediately after interventional treatment. The aim of this study was to assess whether the results of QuBE analysis might predict the development of heart failure (HF) in AMI patients in 3 year-long follow-up.
METHODS
Ninety five patients with first AMI, single vessel coronary artery disease, Killip class I at presentation were enrolled in the study. Angiograms were reanalyzed using the on-line QuBE software. Data on heart failure development (ICD 10 codes I50) provided by the National Health Fund were considered as primary outcome.
RESULTS
QuBE values ranged from 0.0 to 25.3 arbitrary units, mean value was 9.9 ± 5.2 arbitrary units. QuBE correlated positively with myocardial blush grade (MBG; Spearman R = 0.342 at p < 0.05). Multivariate Cox proportional hazard modeling, adjusted for initial Thrombolysis in Myocardial In-farction (TIMI flow, and TIMI thrombus grade indicated QuBE score (1 unit increase - HR 0.919, 95% CI 0.846-0.999, p = 0.049) and left ventricular ejection fraction at discharge (1% increase - HR 0.936, 95% CI 0.902-0.971, p = 0.000) as independent predictors of HF development.
CONCLUSIONS
The QuBE assessment of myocardial perfusion allows the prediction of HF development in the post-infarction period in this highly selective group of patients.

Identifiants

pubmed: 29131283
pii: VM/OJS/J/50232
doi: 10.5603/CJ.a2017.0129
pmc: PMC8084370
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

322-332

Références

Circulation. 2003 Apr 29;107(16):2115-9
pubmed: 12695301
Eur Heart J. 2012 Dec;33(24):3054-61
pubmed: 22991455
Circulation. 1996 Mar 1;93(5):879-88
pubmed: 8598078
Eur Heart J. 2012 Dec;33(23):2928-38
pubmed: 22453653
J Am Coll Cardiol. 2011 Aug 9;58(7):692-703
pubmed: 21816304
Catheter Cardiovasc Interv. 2011 Feb 1;77(2):174-81
pubmed: 20518003
Eur J Echocardiogr. 2008 Jul;9(4):438-48
pubmed: 18579482
Circulation. 2004 Mar 9;109(9):1121-6
pubmed: 14967718
Ups J Med Sci. 2009;114(3):149-53
pubmed: 19736604
J Am Coll Cardiol. 2008 Feb 5;51(5):552-9
pubmed: 18237684
Coron Artery Dis. 2011 May;22(3):171-8
pubmed: 21394026
N Engl J Med. 1987 Oct 22;317(17):1098
pubmed: 3657876
Eur Heart J. 2010 Nov;31(21):2660-8
pubmed: 20675660
Int J Cardiovasc Imaging. 2012 Apr;28(4):835-42
pubmed: 21643941
Clin Res Cardiol. 2014 May;103(5):373-80
pubmed: 24435358
J Am Coll Cardiol. 2007 Aug 14;50(7):573-83
pubmed: 17692740
Kardiol Pol. 2006 Apr;64(4):383-8; discussion 389-90
pubmed: 16699982
Am J Cardiol. 2006 Apr 1;97(7):977-80
pubmed: 16563899
Circulation. 2002 Dec 10;106(24):3051-6
pubmed: 12473550
J Am Coll Cardiol. 2005 Feb 15;45(4):508-14
pubmed: 15708696
J Am Coll Cardiol. 2015 Mar 17;65(10):963-72
pubmed: 25766941
Am Heart J. 2011 Oct;162(4):663-70
pubmed: 21982658
Am Heart J. 2011 Aug;162(2):372-381.e2
pubmed: 21835300
N Engl J Med. 2015 Apr 9;372(15):1389-98
pubmed: 25853743
Circulation. 2001 May 29;103(21):2550-4
pubmed: 11382722
Eur Heart J. 2016 Apr 1;37(13):1024-33
pubmed: 26364289
Eur Heart J. 2009 Mar;30(5):594-9
pubmed: 19168868
Circulation. 1998 Jun 16;97(23):2302-6
pubmed: 9639373
Can J Cardiol. 2008 Aug;24(8):633-9
pubmed: 18685744
Neth Heart J. 2010 Jan;18(1):25-30
pubmed: 20111640
JACC Cardiovasc Interv. 2013 Jul;6(7):718-24
pubmed: 23866184
J Am Coll Cardiol. 2000 Mar 1;35(3):569-82
pubmed: 10716457
Eur Heart J. 2008 Mar;29(6):748-56
pubmed: 18308687
J Am Coll Cardiol. 2008 Feb 5;51(5):560-5
pubmed: 18237685
Rev Esp Cardiol. 2006 Jun;59(6):575-81
pubmed: 16790201
Circulation. 2016 Dec 6;134(23):1833-1847
pubmed: 27803036
Lancet. 2008 Jun 7;371(9628):1915-20
pubmed: 18539223
Lancet. 1997 Aug 30;350(9078):615-9
pubmed: 9288043

Auteurs

Andrzej Tomasik (A)

2nd Department of Cardiology in Zabrze, Medical Faculty with Dentistry Division in Zabrze, Medical University of Silesia, Katowice, Poland. tomasik@poczta.onet.pl.

Tomasz Młyńczak (T)

Students' Scientific Group at 2nd Department of Cardiology in Zabrze, Medical Faculty with Dentistry Division in Zabrze, Medical University of Silesia, Katowice, Poland.

Edyta Nowak (E)

Students' Scientific Group at 2nd Department of Cardiology in Zabrze, Medical Faculty with Dentistry Division in Zabrze, Medical University of Silesia, Katowice, Poland.

Katarzyna Pigoń (K)

Students' Scientific Group at 2nd Department of Cardiology in Zabrze, Medical Faculty with Dentistry Division in Zabrze, Medical University of Silesia, Katowice, Poland.

Artur Iwasieczko (A)

Students' Scientific Group at 2nd Department of Cardiology in Zabrze, Medical Faculty with Dentistry Division in Zabrze, Medical University of Silesia, Katowice, Poland.

Mariusz Opara (M)

2nd Department of Cardiology in Zabrze, Medical Faculty with Dentistry Division in Zabrze, Medical University of Silesia, Katowice, Poland.

Ewa Nowalany-Kozielska (E)

2nd Department of Cardiology in Zabrze, Medical Faculty with Dentistry Division in Zabrze, Medical University of Silesia, Katowice, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH